FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309676723> ?p ?o ?g. }

• W4309676723 abstract "SUMMARY Background This COVID-19 pandemic has caused unprecedented morbidity, mortality, and global economic instability. Several approved vaccines demonstrated to be effective prevention against COVID-19. We aimed to evaluate the safety and immunogenicity of the PIKA-adjuvanted recombinant SARS-C0V-2 Spike (S) protein subunit vaccine in adults as a primary immunization and as a booster dose against SARS-C0V-2 infection. Methods This was a Phase I, open label, dose-escalation study of 3 dose levels of the SARS-CoV-2 spike antigen administered intramuscularly in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety, tolerability, and immunogenicity of PIKA COVID-19 vaccine candidate in healthy adults. The study planned to have 3 arms: Arm A included subjects who had never received any Covid 19 vaccination or have had Covid 19 infection for > 6 months prior to enrolment, Arm B1 included subjects who had completed their primary series of Covid 19 vaccination with an inactivated Covid 19 vaccine and Arm B2 which included subjects whose primary series was completed with mRNA Covid 19 vaccine. The primary safety outcome was adverse events and safety laboratory parameters, and the secondary immunogenicity outcome was neutralizing antibody geometric mean titers and seroconversion rates against the wild type virus, Delta and Omicron variants. This trial is registered with ClinicalTrials.gov , number NCT05305300 . Findings This interim analysis report presented the results of Arm A and Arm B1 who completed Day 35 for 2 doses in Arm A and Day 28 for a single booster dose in Arm B1. Safety results Arm A: 60% of participants reported mainly solicited AEs after first and second vaccine. Most of those were local (mainly pain/tenderness) with few systemic (mainly fever and headaches). The majority of participants reported unsolicited events after vaccine which were mainly investigations in hematology/hepatobiliary/Renal or Urine tract infection urine analysis. At least 80% of the participants reported mild AEs. There were 4 SAEs that were mild and were resolved. Also there were 2 medically attended AEs. Arm B1: Less than 50% of the participants reported solicited adverse events which were mainly local (pain and tenderness) and were mild. Also, less than half of the participants reported unsolicited events which were mainly inves-tigations in hematology/hepatobiliary/Renal or Urine tract infection urine analysis. There were no SAE and Medically attended AEs reported. Immunogenicity results Arm A: The neutralizing antibody GMTs at day 35 were substantially higher than those at baseline for all dose groups and all variants. Seroconversion rates at 35 days ranged between 85.7% and 92.9% for 5μg dose group, 92.9% and 100% for the 10μg dose group and between 70% and 80% for the high dose group. Arm B1: Similar to Arm A, neutralizing antibody GMTs at day 28 were substantially higher than those at baseline for all dose groups and all variants. Seroconversion rates at 28 days ranged between 92.9% and 100% for 5μg dose group, 80% and 100% for the 10μg dose group and between 50% and 64.3% for the high dose group. Conclusion The findings demonstrated that the PIKA Covid 19 vaccine is safe, well tolerated, immunogenic and can be used as a primary vaccination or as a booster dose in participants who had completed an inactivated Covid 19 vaccination series. A comparison of the immune responses presented in this interim analysis showed that geometric mean titer (GMTs) of neutralizing antibody against wild type of SARS-CoV-2 virus, Delta and Omicron of the 5μg group was higher than the 10 μg and 20 μg, therefore the 5μg was selected as the recommended dose for the Phase II and III clinical development of the PIKA Covid 19 vaccine." @default.
• W4309676723 created "2022-11-29" @default.
• W4309676723 creator A5009318195 @default.
• W4309676723 creator A5032223866 @default.
• W4309676723 creator A5044544424 @default.
• W4309676723 creator A5046214153 @default.
• W4309676723 creator A5061729979 @default.
• W4309676723 date "2022-11-22" @default.
• W4309676723 modified "2023-09-27" @default.
• W4309676723 title "Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial" @default.
• W4309676723 cites W2047815636 @default.
• W4309676723 cites W2081141733 @default.
• W4309676723 cites W3046463683 @default.
• W4309676723 cites W3117978409 @default.
• W4309676723 cites W3154522465 @default.
• W4309676723 doi "https://doi.org/10.1101/2022.11.20.22282565" @default.
• W4309676723 hasPublicationYear "2022" @default.
• W4309676723 type Work @default.
• W4309676723 citedByCount "1" @default.
• W4309676723 countsByYear W43096767232023 @default.
• W4309676723 crossrefType "posted-content" @default.
• W4309676723 hasAuthorship W4309676723A5009318195 @default.
• W4309676723 hasAuthorship W4309676723A5032223866 @default.
• W4309676723 hasAuthorship W4309676723A5044544424 @default.
• W4309676723 hasAuthorship W4309676723A5046214153 @default.
• W4309676723 hasAuthorship W4309676723A5061729979 @default.
• W4309676723 hasBestOaLocation W43096767231 @default.
• W4309676723 hasConcept C12590561 @default.
• W4309676723 hasConcept C126322002 @default.
• W4309676723 hasConcept C147483822 @default.
• W4309676723 hasConcept C159047783 @default.
• W4309676723 hasConcept C197934379 @default.
• W4309676723 hasConcept C203014093 @default.
• W4309676723 hasConcept C22070199 @default.
• W4309676723 hasConcept C2522874641 @default.
• W4309676723 hasConcept C2777451964 @default.
• W4309676723 hasConcept C2778375690 @default.
• W4309676723 hasConcept C2780801004 @default.
• W4309676723 hasConcept C2780868878 @default.
• W4309676723 hasConcept C535046627 @default.
• W4309676723 hasConcept C61943457 @default.
• W4309676723 hasConcept C71924100 @default.
• W4309676723 hasConceptScore W4309676723C12590561 @default.
• W4309676723 hasConceptScore W4309676723C126322002 @default.
• W4309676723 hasConceptScore W4309676723C147483822 @default.
• W4309676723 hasConceptScore W4309676723C159047783 @default.
• W4309676723 hasConceptScore W4309676723C197934379 @default.
• W4309676723 hasConceptScore W4309676723C203014093 @default.
• W4309676723 hasConceptScore W4309676723C22070199 @default.
• W4309676723 hasConceptScore W4309676723C2522874641 @default.
• W4309676723 hasConceptScore W4309676723C2777451964 @default.
• W4309676723 hasConceptScore W4309676723C2778375690 @default.
• W4309676723 hasConceptScore W4309676723C2780801004 @default.
• W4309676723 hasConceptScore W4309676723C2780868878 @default.
• W4309676723 hasConceptScore W4309676723C535046627 @default.
• W4309676723 hasConceptScore W4309676723C61943457 @default.
• W4309676723 hasConceptScore W4309676723C71924100 @default.
• W4309676723 hasLocation W43096767231 @default.
• W4309676723 hasOpenAccess W4309676723 @default.
• W4309676723 hasPrimaryLocation W43096767231 @default.
• W4309676723 hasRelatedWork W2049563665 @default.
• W4309676723 hasRelatedWork W2114021231 @default.
• W4309676723 hasRelatedWork W2173699645 @default.
• W4309676723 hasRelatedWork W2334977059 @default.
• W4309676723 hasRelatedWork W2368098075 @default.
• W4309676723 hasRelatedWork W2388122170 @default.
• W4309676723 hasRelatedWork W2991006761 @default.
• W4309676723 hasRelatedWork W4205870633 @default.
• W4309676723 hasRelatedWork W4210467545 @default.
• W4309676723 hasRelatedWork W4210690844 @default.
• W4309676723 isParatext "false" @default.
• W4309676723 isRetracted "false" @default.
• W4309676723 workType "article" @default.